ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

ClinicalTrials.gov ID: NCT03127267

Public ClinicalTrials.gov record NCT03127267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Study identification

NCT ID
NCT03127267
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AB Science
Industry
Enrollment
495 participants

Conditions and interventions

Interventions

  • Masitinib (4.5) Drug
  • Masitinib (6.0) Drug
  • Placebo Drug
  • Riluzole Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 81 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 1, 2021
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027
Last update posted
Sep 11, 2025

2021 – 2027

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294 Recruiting
University of Southern California Los Angeles California 90007 Recruiting
University of Kentucky Lexington Kentucky 40506 Recruiting
Johns Hopkins Medicine Brain Science Institute Baltimore Maryland 21205 Recruiting
Lahey Hospital and Medical Center Burlington Massachusetts 01805 Recruiting
University of Virginia Health System Charlottesville Virginia 22903 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03127267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 11, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03127267 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →